Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Lung Cancer, Surgery, Blood Pressure Management, Dexamethasone, Overall Survival, Postoperative Complications

In brief

Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.

Key facts

Study ID

NCT04209218

Run by

Peking University First Hospital

People needed

1988

Starts

2020-04-07

Expected to finish

2029-12-01

Last updated by the study team

2025-07-31

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged >50 years but <90 years.
• Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of >2 hours.
• Agree to participate in this study and sign the informed consent.

You may not qualify if…

• Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery.
• Recurrent or metastatic lung cancer.
• History of cancer or complicated with cancer in other organs.
• Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation.
• Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg); or requirement of vasopressors to maintain blood pressure.
• Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months.
• Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy).
• Any other circumstances considered unsuitable for study participation by attending physicians or investigators.

Where it is running

• Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.